EMA Wants Authority To Request Modifications To Agreed PIPs
This article was originally published in SRA
Executive Summary
As the time draws near for the 10-year review of the EU Paediatric Regulation, the European Medicines Agency has indicated certain changes that it would like the legislation to support in the future.
You may also be interested in...
Is €20m A Reasonable Cost For An EU PIP? Consultation On Pediatric Rule
Biosimilars, the complicated rewards system, and the costs for companies involved in carrying out a pediatric investigation plan are among the many issues discussed in the European Commission’s newly released consultation on the Paediatric Regulation nearly 10 years after it came into force.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.